HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kenneth B Gordon Selected Research

briakinumab

2/2012A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.
8/2011Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
2/2011Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial.
3/2010Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
2/2008Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kenneth B Gordon Research Topics

Disease

88Psoriasis (Pustulosis Palmaris et Plantaris)
06/2022 - 01/2002
10Infections
07/2016 - 11/2003
8Psoriatic Arthritis
01/2020 - 03/2006
7Neoplasms (Cancer)
09/2014 - 01/2002
4Inflammation (Inflammations)
01/2018 - 11/2007
3Rheumatoid Arthritis
01/2020 - 01/2004
3Skin Neoplasms (Skin Cancer)
04/2013 - 02/2012
2Pain (Aches)
12/2020 - 01/2007
2Hidradenitis Suppurativa
01/2020 - 12/2003
2Ankylosing Spondylitis
01/2020 - 04/2013
2Crohn Disease (Crohn's Disease)
01/2020 - 04/2013
2Skin Diseases (Skin Disease)
06/2017 - 01/2008
2Melanoma (Melanoma, Malignant)
09/2014 - 04/2013
2Stroke (Strokes)
03/2012 - 08/2011
2Myocardial Infarction
03/2012 - 08/2011
2Pruritus (Itching)
01/2007 - 12/2003
2Wounds and Injuries (Trauma)
09/2006 - 12/2002
1Oral Candidiasis (Thrush)
01/2022
1Chronic Disease (Chronic Diseases)
01/2022
1Ulcerative Colitis
01/2020
1Non-Radiographic Axial Spondyloarthritis
01/2020
1Uveitis
01/2020
1Acne Vulgaris
06/2018
1Rosacea (Acne Rosacea)
06/2018
1Cellulite
06/2018
1Necrosis
01/2018
1Neutropenia
07/2016
1Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
07/2016
1Lymphoma (Lymphomas)
04/2013
1Juvenile Arthritis (Juvenile Idiopathic Arthritis)
04/2013
1Arthritis (Polyarthritis)
04/2013
1Nail Diseases (Nail Disease)
12/2012
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
12/2012
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
02/2012

Drug/Important Bio-Agent (IBA)

13Biological ProductsIBA
01/2021 - 05/2002
12Ustekinumab (CNTO 1275)FDA Link
01/2021 - 05/2008
11Adalimumab (Humira)FDA Link
01/2020 - 01/2004
10Interleukin-23 (Interleukin 23)IBA
02/2022 - 03/2010
10Monoclonal AntibodiesIBA
01/2018 - 01/2004
9CytokinesIBA
12/2019 - 09/2003
9efalizumab (Raptiva)FDA Link
09/2009 - 12/2003
8Interleukin-12 (IL 12)IBA
09/2018 - 02/2008
8Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2018 - 01/2004
7Alefacept (Amevive)FDA Link
09/2009 - 11/2003
6guselkumabIBA
12/2020 - 07/2015
6Etanercept (Enbrel)FDA Link
07/2016 - 12/2003
5risankizumabIBA
06/2022 - 01/2018
5Immunoglobulin A (IgA)IBA
01/2021 - 12/2019
5Interleukin-17 (Interleukin 17)IBA
01/2021 - 07/2013
5InterleukinsIBA
06/2018 - 05/2008
5Tumor Necrosis Factor InhibitorsIBA
06/2018 - 01/2006
5ixekizumabIBA
11/2016 - 03/2014
5briakinumabIBA
02/2012 - 02/2008
4Methotrexate (Mexate)FDA LinkGeneric
12/2017 - 01/2002
3bimekizumabIBA
01/2022 - 01/2021
3apremilastIBA
06/2020 - 03/2014
3Pharmaceutical PreparationsIBA
02/2018 - 12/2003
3Immunoglobulin G (IgG)IBA
01/2018 - 11/2003
3Prostaglandins AIBA
07/2015 - 04/2007
3Infliximab (Remicade)FDA Link
09/2009 - 12/2003
3Proteins (Proteins, Gene)FDA Link
01/2004 - 05/2002
2secukinumabIBA
02/2022 - 03/2014
24-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA
12/2020 - 12/2020
2Hydroxyurea (Hydrea)FDA LinkGeneric
06/2020 - 09/2009
2Mycophenolic Acid (Cellcept)FDA LinkGeneric
06/2020 - 09/2009
2Leflunomide (Arava)FDA LinkGeneric
06/2020 - 09/2009
2tofacitinibIBA
06/2020 - 03/2014
2FumaratesIBA
06/2020 - 09/2009
2Tacrolimus (Prograf)FDA LinkGeneric
06/2020 - 09/2009
2Thioguanine (Tioguanine)FDA Link
06/2020 - 09/2009
2Type 4 Cyclic Nucleotide PhosphodiesterasesIBA
07/2015 - 03/2014
2omega-Chloroacetophenone (Mace)IBA
03/2012 - 08/2011
2SteroidsIBA
05/2008 - 01/2007
1TYK2 Kinase (Tyrosine Kinase 2)IBA
02/2022
1deucravacitinibIBA
02/2022
1Interleukin-22 (IL-22)IBA
12/2019
1Photosensitizing Agents (Photosensitizers)IBA
09/2019
1Interleukin-23 Subunit p19IBA
09/2018
1Phosphodiesterase 4 InhibitorsIBA
07/2015
1Phosphotransferases (Kinase)IBA
03/2014
1brodalumabIBA
03/2014
1Janus Kinase InhibitorsIBA
03/2014
1tildrakizumabIBA
03/2014
1Antigen-Antibody Complex (Immune Complex)IBA
07/2013
16-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA
08/2011
1AntibodiesIBA
03/2010
1Azathioprine (Imuran)FDA LinkGeneric
09/2009
1Sulfasalazine (Azulfidine)FDA LinkGeneric
09/2009

Therapy/Procedure

42Therapeutics
01/2022 - 01/2002
10Biological Therapy
02/2018 - 05/2002
6Phototherapy (Light Therapy)
01/2022 - 12/2004
4Retreatment
03/2017 - 01/2006
2Excimer Lasers
09/2019 - 01/2010
2Subcutaneous Injections
07/2010 - 01/2004
2Immunotherapy
09/2009 - 08/2003
1Complementary Therapies (Alternative Medicine)
02/2021
1Aftercare (After-Treatment)
12/2019
1Dye Lasers
09/2019
1Electrodes (Electrode)
09/2019
1Photochemotherapy (Photodynamic Therapy)
01/2010